{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:25:18Z","timestamp":1787397918268,"version":"build-2736575974"},"reference-count":28,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008659","name":"European Committee for Treatment and Research in Multiple Sclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","award":["24-PDF-0166"],"award-info":[{"award-number":["24-PDF-0166"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010443","name":"RACP Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010443","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service England."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The effects of smoking and vascular risk factors (VRF) on relapse activity in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are not well understood. We aimed to investigate these.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>MOGAD patients in the Oxford National Neuromyelitis Optica (NMO) Service with known smoking or VRF (hypertension, hypercholesterolaemia, type 2 diabetes, elevated body mass index) status were considered for inclusion. Outcomes were time-to-relapsing course and relapse rate. Cox and negative binomial regression were utilised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 172 patients. Current smokers had a 2.2 times higher relapse rate than never smokers (adjusted rate ratio 2.23 [95% CI\u2009=\u20091.35\u20133.68],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0017). Relapse rate was similar between past and never smokers (adjusted rate ratio 0.81 [0.51\u20131.29],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.38). For time-to-relapsing course, multivariable analysis did not identify smoking as associated although univariable analysis showed a consistent trend with shorter time-to-relapse in current than never smokers (hazard ratio 1.76 [0.97\u20133.22],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.06). There was no difference in either outcome by VRF status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Relapse rates were doubled in current than never smokers, whereas these were similar between past and never smokers. VRF did not associate with relapse risk. Smoking cessation should be encouraged in current smokers with MOGAD as past smokers were not observed with this poorer outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261429292","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:07:56Z","timestamp":1775545676000},"page":"794-805","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-6612","authenticated-orcid":false,"given":"Wei Zhen","family":"Yeh","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-7783","authenticated-orcid":false,"given":"Fiona","family":"Chan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Francis","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-8727","authenticated-orcid":false,"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-808X","authenticated-orcid":false,"given":"Ruth","family":"Geraldes","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Leite","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Banwell B Bennett JL Marignier R et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268\u2013282 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1474442222004318 (accessed 29 January 2023).","DOI":"10.1016\/S1474-4422(22)00431-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42780"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000013"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","unstructured":"Trewin BP Dale RC Qiu J et al. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse. J Neurol Neurosurg Psychiatry 2024; 95: 1054\u20131063 https:\/\/jnnp.bmj.com\/content\/early\/2024\/05\/16\/jnnp-2024-333463 (accessed 17 May 2024).","DOI":"10.1136\/jnnp-2024-333463"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awag006"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251325069"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102773"},{"key":"e_1_3_3_11_2","unstructured":"R Core Team. R: A language and environment for statistical computing 2024 https:\/\/www.R-project.org\/"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686"},{"key":"e_1_3_3_13_2","unstructured":"Therneau T. A package for survival analysis in R 2024 https:\/\/CRAN.R-project.org\/package=survival"},{"key":"e_1_3_3_14_2","unstructured":"Venables WN Ripley BD. Modern applied statistics with S. New York: Springer 2002 http:\/\/link.springer.com\/10.1007\/978-0-387-21706-2 (accessed 21 September 2025)."},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Cacciaguerra L Redenbaugh V Chen JJ et al. Timing and predictors of T2-lesion resolution in patients with myelin-oligodendrocyte-glycoprotein-antibody-associated disease. Neurology 2023;101: e1376\u2013e1381 https:\/\/n-neurology-org.ap1.proxy.openathens.net\/content\/early\/2023\/06\/16\/WNL.0000000000207478 (accessed 9 July 2023).","DOI":"10.1212\/WNL.0000000000207478"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231188485"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02284-1"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-11-200306030-00010"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Kang Y-R Kim KH Hyun J-W et al. Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: A case series. Mult Scler Relat Disord 2024; 91: 105859 https:\/\/www.msard-journal.com\/article\/S2211-0348(24)00436-X\/fulltext (accessed 30 September 2025).","DOI":"10.1016\/j.msard.2024.105859"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","unstructured":"McLendon LA Gambrah-lyles C Viaene A et al. Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease. Neurol Neuroimmunol Neuroinflamm 2023; 10(6): e200150 https:\/\/nn.neurology.org\/content\/10\/6\/e200150 (accessed 18 August 2023).","DOI":"10.1212\/NXI.0000000000200150"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102483"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06968-8"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Petersen ER S\u00f8ndergaard HB Laursen JH et al. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler J 2018; 25: 1298\u20131305 https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458518791753?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed (accessed 30 September 2025).","DOI":"10.1177\/1352458518791753"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004949"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Pauli FD Reindl M Ehling R et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler J 2008; 14: 1026\u20131030 https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458508093679?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed (accessed 3 August 2025).","DOI":"10.1177\/1352458508093679"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez557"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180262"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70214"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261429292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261429292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261429292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:16:07Z","timestamp":1787397367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261429292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/13524585261429292"],"URL":"https:\/\/doi.org\/10.1177\/13524585261429292","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}